Company Overview and News

 
BDR / Blonder Tongue Laboratories, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

22h fintel.io
Blonder Tongue Laboratories, Inc. (AMEX:BDR) has 11 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,218,320 shares. Largest shareholders include Walker Stephen Eugene, Renaissance Technologies LLC, Citadel Advisors Llc, Virtu Financial LLC, Susquehanna International Group, Llp, Two Sigma Securities, Llc, California Public Employees Retirement System, UBS Group AG, Acadian Asset Management Llc, and Federated Investors Inc /pa/.
Upvote Downvote

 
The Top 5 Bank Earnings Charts

2018-04-11 zacks
Despite the economy being the strongest it’s been in over 10 years; the financial stocks have faltered in 2018.
Upvote Downvote

2
NFEC / NF Energy Saving Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
NF Energy Saving Corp. (NASDAQ:NFEC) has 5 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,415,782 shares. Largest shareholders include Liaoning Nengfa Weiye New Energy Application Co Ltd, Renaissance Technologies LLC, Deutsche Bank Ag\, Virtu Financial LLC, and Morgan Stanley.
Upvote Downvote

 
Bull of the Day: SodaStream (SODA)

2018-04-11 zacks
SodaStream International Limited (SODA - Free Report) has found its niche as health and wellness trends have boosted sales of its sparkling water system. This Zacks Rank #1 (Strong Buy) is expected to grow revenue by the double digits in 2018. SodaStream makes and distributes home beverage carbonation systems called Sparkling Water Makers. These allow consumers to turn tap water into sparkling water and flavored sparkling water.
Upvote Downvote

 
5 Charts to Kick Off Earnings Season

2018-04-10 zacks
Without Alcoa to lead off the Dow, the big banks basically kick off earnings season now.
Upvote Downvote

 
Get Long Vol With Virtu Financial Going Into Q1 Earnings

2018-04-10 seekingalpha
A consistently profitable business model with the benefit of increased profitability during market uncertainty makes it an ideal hedge to diversify a portfolio.
Upvote Downvote

 
Top Stock Picks for the Week of April 9th

2018-04-10 zacks
Paycom Software, Inc. (PAYC - Free Report) ,is a provider of a cloud-based human capital management software solution delivered as Software-as-a-Service. This Zacks #1, Strong Buy, is a cash rich company with a strong balance sheet. It has displayed steady revenue growth and its stock has outperformed the broader market over the last year. Based on our latest consensus estimates, we expect the company to witness solid EPS and revenue growth in its current fiscal year.
Upvote Downvote

 
EFZ / ProShares Short MSCI EAFE - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-10 fintel.io
ProShares Short MSCI EAFE (NYSE:EFZ) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 308,197 shares. Largest shareholders include Morgan Stanley, Wells Fargo & Company/mn, Virtu Financial LLC, Brinker Capital Inc, Susquehanna International Group, Llp, Jane Street Group, Llc, IndexIQ Advisors LLC, Wedbush Securities Inc, LPL Financial LLC, and Envestnet Asset Management Inc.
Upvote Downvote

 
Bull of the Day: Stoneridge (SRI)

2018-04-10 zacks
With the recent market volatility, investors are looking for a safe bet. While we all know that volatility can put pressure on stocks everywhere, we also know that those stocks with solid underlying earnings have a great chance of weathering the storm. In fact, periods of market volatility provide fantastic buying opportunities for stocks like this. By leaning on the Zacks Rank, you can uncover stocks with earnings estimates moving in a positive direction.
Upvote Downvote

 
The 5 Best Stocks to Trade This Week

2018-04-09 zacks
Happy Monday everybody! Coming up the week of April 9, 2018, we have what I like to call the soft start to earnings season. Every season, this is marked by the big bank stocks kicking off. Most of the action happens on Friday before the market opens with JPMorgan Chase (JPM - Free Report) , Wells Fargo (WFC - Free Report) , and Citigroup (C - Free Report) . Earlier in the week we will see reports from Delta Airlines (DAL - Free Report) as well as retailer Bed, Bath, and Beyond (BBBY - Free Report) .
Upvote Downvote

 
OGEN / Oragenics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-09 fintel.io
Oragenics, Inc. (AMEX:OGEN) has 20 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,113,123 shares. Largest shareholders include Third Security, LLC, Koski Family Lp, MSD Partners, L.P., FMR LLC / Fidelity, Sabby Management, LLC, Bank of New York Mellon Corp, Vanguard Group Inc, Virtu Financial LLC, Citadel Advisors Llc, and Northern Trust Corp.
Upvote Downvote

 
Bull of the Day: General Motors (GM)

2018-04-09 zacks
Headquartered in Detroit, MI,General Motors (GM - Free Report) is one of the largest automakers in the world with more than 180,000 employees and 12,450 dealers in 125 countries.
Upvote Downvote

 
Bull of the Day: Centene (CNC)

2018-04-06 zacks
Centene (CNC - Free Report) is one of the largest managed care providers in the US, serving over 12 million people in 14 states. In addition to being the largest Medicaid Managed Care Organization in the country, Centene is also the largest carrier on the Health Insurance Marketplace and a national leader in managed long-term services and supports. Centene delivered another strong quarter and outlook on February 6 and analysts responded by raising 2018 full-year earnings estimates 21% from $5.
Upvote Downvote

 
Virtu Financial (VIRT) and Flotek (FTK) are Aggressive Growth Stocks

2018-04-06 zacks
Brian Bolan, the aggressive growth stock strategist at Zacks Investment Research takes a look at two new names to put on your aggressive growth stock radar. First is Virtu Financial (VIRT - Free Report) which is a high frequency trading firm. Brian believes that this name will tell very well given the recent volatility in the market. He also likes the recent beats and is overlooking the growth style score that should be much higher given the posted revenue growth.
Upvote Downvote

 
After More Than a Decade of Insane Growth, Is Apple's Revenue Finally Plateauing?

2018-04-05 zacks
Apple’s (AAPL - Free Report) outsized growth since the iPhone launched has seen it become the world’s most valuable company, worth more than Amazon (AMZN - Free Report) , Alphabet (GOOGL - Free Report) , and all the other tech giants. But nothing last forever, so let’s take a look at just how much Apple has grown since then, and see if these days are numbered.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 928254101